

DESCRIPTION

Source *E. coli*-derived feline IL-6 protein
Thr28-Met208 (Glu133Lys), with an N-terminal Met
Accession # P41683

N-terminal Sequence Analysis Met

Predicted Molecular Mass 20.7 kDa

SPECIFICATIONS

Activity Measured in a cell proliferation assay using T1165.85.2.1 mouse plasmacytoma cells. Nordan, R.P. *et al.* (1987) *J. Immunol.* **139**:813. The ED₅₀ for this effect is 0.300-3.00 ng/mL.

Endotoxin Level <1.0 EU per 1 µg of the protein by the LAL method.

Purity >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 100 µg/mL in sterile PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Interleukin-6 (IL-6) is a pleiotropic, α-helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression (1-5). Mature feline IL-6 is 181 amino acids (aa) in length and shares 56%, 35%, 38%, and 76% aa sequence identity with human, mouse, rat, and canine IL-6, respectively (6, 7). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 Rα) and a signal transducing subunit (gp130). IL-6 binds to IL-6 Rα, triggering IL-6 Rα association with gp130 and gp130 dimerization (8). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (9). Soluble forms of IL-6 Rα are generated by both alternative splicing and proteolytic cleavage (5). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 Rα elicit responses from gp130-expressing cells that lack cell surface IL-6 Rα (5). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 Rα is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes (2, 5). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 Rα but not from other cytokines that use gp130 as a co-receptor (5, 10). IL-6, along with TNF-α and IL-1, drives the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease (1-5). When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis (1, 2, 5). IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise (2). In addition, it enhances hematopoietic stem cell proliferation and the differentiation of Th17 cells, memory B cells, and plasma cells (1, 11).

References:

1. Mansell, A. and B.J. Jenkins (2013) *Cytokine Growth Factor Rev.* **24**:249.
2. Schuett, H. *et al.* (2009) *Thromb. Haemost.* **102**:215.
3. Erta, M. *et al.* (2012) *Int. J. Biol. Sci.* **8**:1254.
4. Garbers, C. *et al.* (2012) *Cytokine Growth Factor Rev.* **23**:85.
5. Mihara, M. *et al.* (2012) *Clin. Sci. (Lond.)* **122**:143.
6. Ohashi, T. *et al.* (1993) *J. Vet. Med. Sci.* **55**:941.
7. Bradley, W.G. *et al.* (1993) *Proc. Soc. Exp. Biol. Med.* **204**:301.
8. Murakami, M. *et al.* (1993) *Science* **260**:1808.
9. Muller-Newen, G. (2003) *Sci. STKE* **2003**:PE40.
10. Mitsuyama, K. *et al.* (2006) *Clin. Exp. Immunol.* **143**:125.
11. Cerutti, A. *et al.* (1998) *J. Immunol.* **160**:2145.